How a protein called CD74 affects recovery from traumatic brain injury
Mechanisms by which CD74 Contributes to Traumatic Brain Injury
This study is looking at a protein called CD74 to see how it affects healing and inflammation after a traumatic brain injury, with the hope of finding new ways to help people recover better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-10493357 on NIH RePORTER |
What this research studies
This research investigates the role of CD74, a protein involved in the immune response, in the aftermath of traumatic brain injury (TBI). The study aims to understand how CD74 contributes to inflammation and neurodegeneration following TBI, with the goal of identifying potential therapeutic targets. By examining both innate and adaptive immune responses, the researchers hope to develop strategies that could improve recovery outcomes for individuals affected by TBI. The approach includes both laboratory studies and analysis of data from human patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced a traumatic brain injury and are dealing with its chronic effects.
Not a fit: Patients who have not suffered a traumatic brain injury or those with pre-existing neurological conditions unrelated to TBI may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance recovery and reduce long-term complications for patients with traumatic brain injury.
How similar studies have performed: Previous research has shown promising results in manipulating immune responses to improve outcomes in traumatic brain injury, suggesting that this approach could be effective.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Newell Rogers, M. Karen — Texas A&m University Health Science Ctr
- Study coordinator: Newell Rogers, M. Karen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.